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Abstract 
Vaccine potency and safety testing is characterized by extensive use of laboratory animals and a relatively high percentage of test 
methods that involve severe pain and distress. This is particularly true for tests that are based on infection or challenge with a 
virulent microorganism. Traditionally, vaccine potency tests on inactivated vaccines require a vaccination–challenge procedure 
using severe clinical signs or even lethality as endpoints.  
For several of these vaccines, 3R methods have been developed that include a nonclinical endpoint, ultimately resulting in 
reduction of animal numbers and a significant decrease in severity level. An example is the use of serology in potency testing of 
tetanus and diphtheria toxoid vaccines. 
For some potency tests, however, replacement of the challenge procedure is not (yet) possible, and the implementation of humane 
endpoints might be an approach to limit the level and duration of pain and distress. The application of these endpoints is now 
allowed in most pharmacopoeias.  
Establishing humane endpoints in vaccine potency testing requires the identification of parameters that are predictive of death, or 
severe clinical signs, in the animal during the observation period. As a case study, we present the results of work we performed 
on the identification of humane endpoints in whole cell pertussis (wP) vaccine potency testing (the mouse protection test or the 
Kendrick test). In this potency test, mice are challenged by intracerebral route 14 days after immunization with a lethal dose of 
virulent B. pertussis microorganisms. Animals are observed for 14 days, and the number of mice per dose group surviving this 
period is used for probit analysis and estimation of potency. 
We have studied two types of humane endpoints: clinical signs and pathophysiological parameters (body weight and body 
temperature). Clinical signs in a wP potency test range from piloerection, hunched back posture, apathy, and convulsions to 
moribund condition. Also body temperature drops, and animals lose up to 50% of their body weight post-challenge.  
Parameters were “validated” for relevance (prediction of death within the observation period) and reliability. Recommendations 
are given for implementation of humane endpoints in vaccine potency testing, also taking into account potential obstacles.  
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1. Introduction 
Refinement of animal procedures is one of the leading ethical principles in biomedical research when animal 
replacement alternatives are not available. From an animal welfare point of view, priority should be given to those 
procedures that involve severe pain and distress. According to the statistics on the use of laboratory animals in the 
Netherlands, one of the few countries that keep statistics on severity levels, 11.3% of all animal experiments result 
in severe clinical signs, severe distress, or even lethality [1]. 
An important strategy to limit the level and/or duration of severity is the implementation of humane endpoints. A 
humane endpoint can be defined as ‘‘The earliest indicator in an animal experiment of (potential) pain and/or 
distress that, within its scientific context and moral acceptability, can be used to avoid or limit such consequences by 
taking actions such as humane killing or terminating or alleviating the pain and distress” [2].  
Existing regulations on the use of laboratory animals in biomedical research promote the application of humane 
endpoints. For instance, Article 13.3 of the recently adopted revised regulation on animal experimentation in the 
European Union states that “Death as an end-point shall be avoided as far as possible and replaced by early and 
humane end-points” [3].  
Humane endpoints are case specific and differ depending on the type of research and even on the type of 
experiment or animal model being used. This manuscript will focus on the identification of humane endpoints in 
vaccine potency testing, using the whole cell pertussis (wP) vaccine to illustrate possibilities and limitations.  
2. Humane endpoints in vaccine potency testing  
Significant numbers of laboratory animals are used for vaccine-related purposes. Animals are needed for vaccine 
research and development (R&D), nonclinical testing, and, particularly, for lot release testing required by statute. 
According to statistics in the Netherlands, the vaccines category accounted for about 15% of total laboratory animal 
use in 2009 [1].  
Animal studies in vaccine R&D focus on pathogenicity of the virulent microorganism, antigen selection, antigen 
kinetics, and adjuvant. In nonclinical testing, the focus is on product safety, formulation, and application (dose, route 
of injection). In statutory lot release testing, animal tests are particularly needed to demonstrate potency and safety 
of each lot of vaccine produced. Of the total number of animals used for vaccine-related purposes, it is estimated 
that 30% are used for R&D and preclinical testing and 70% are used for lot release testing (Hoonakker, personal 
communication).  
Due to the type of questions to be addressed in vaccine R&D and lot release testing, infection or challenge with 
the virulent microorganism is frequently performed. Consequently, clinical signs and lethality are common 
phenomena in these studies.  
The animal model most relevant for implementation of humane endpoints is the potency test for lot release of 
inactivated vaccines. The model is generally based on a vaccination–challenge procedure. In short, animals are 
immunized with serial doses of the vaccine being studied and with a reference vaccine with known potency in 
International Units (IU), respectively. Several weeks after immunization, the animals are challenged with a lethal 
dose of virulent microorganisms. Deaths per dose group within a fixed observation period are recorded. The key 
parameter in the challenge test is the dose of vaccine protecting 50% of the animals against the lethal challenge 
(effective dose 50 = ED50). Consequently, in a typical lethal challenge test, about 50% of all vaccinated animals are 
expected to die after challenge. Widely used vaccines incorporating lethal challenge potency testing include wP 
vaccine and rabies vaccines.  
Specifications for test performance are given in the monographs of the European Pharmacopoeia, the Technical 
Report Series of the World Health Organization (WHO), and the U.S. Code of Federal Regulations (CFR) (USDA 
and FDA—rabies vaccine for veterinary use only). In the context of the lethal challenge procedure, it is worth 
mentioning that nonclinical endpoints have been developed for several products, such as tetanus and diphtheria 
toxoid [4, 5]. Assessing potency by serology instead of challenge is accepted for these products by the European 
Pharmacopoeia and the WHO.  
Most guidelines on vaccine quality now allow for the application of humane endpoints. According to 9 CFR 
117.4 (e) (USDA), “test animals that show clinical signs of illness that are due to the test may be treated or 
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humanely destroyed if the illness has progressed to a point … when death is certain to occur without therapeutic 
intervention” [6]. 
In order to identify humane endpoints for potency tests based on a challenge procedure, the working group 
Humane Endpoints for Lethal Parameters (HELP) was established in the late 1990s. The working group was a 
collaboration of the Netherlands Vaccine Institute (NVI, Netherlands), the Paul-Ehrlich Institute (PEI, Germany) 
and the University of Birmingham (UK), with financial support from the European Centre for the Validation of 
Alternative Methods (ECVAM). The focus of the NVI laboratory in the HELP activities was on wP vaccine potency 
testing.  
3. Whole cell pertussis (wP) vaccine potency testing  
In the past, wP vaccine was used worldwide in basic immunization programs. Due to the intrinsic side effects of 
the wP vaccine, an improved vaccine was developed. Nowadays, most Western countries use an improved vaccine, 
the acellular pertussis (aP) vaccine, based on a limited number of antigenic components of Bordetella pertussis. 
Nevertheless, the wP vaccine still is and will be the vaccine of choice in a large part of the world, particularly Third 
World countries, as aP vaccines are far more expensive than wP vaccines. As vaccine manufacturers in Western 
countries produce wP vaccine for export, the lethal challenge test continues to be performed routinely in these 
countries. It is estimated that annual use of animals for this test in Europe number over 100,000 mice [7]. 
The wP potency test, also called the mouse protection test (MPT) or Kendrick test, was developed around 1939 
[8]. Groups of mice are immunized with three or four serial doses of the wP vaccine being studied and the reference 
preparation, respectively. After two weeks, animals are challenged by intracerebral route with 10 μl of 50 times the 
dose of virulent B. pertussis that is lethal for 50% of the animals injected with that dose (50LD50). Intracerebral 
challenge is followed by an observation period of two weeks. The endpoint used is the number of deaths per dose 
group within the observation period. Each test requires at least 120 animals. Additionally, about 40 mice are needed 
for titration of the challenge culture.  
3.1. Selection of humane endpoints 
To identify parameters to be used as humane endpoints in wP potency testing, we divided the study into two 
parts: an evaluation phase and a validation phase [9]. None of the studies required additional animal use because 
they were run in parallel with routine lot release tests. Parameters monitored were clinical signs, body weight, and 
body temperature. These parameters were considered relevant in infectious disease models and are easily monitored 
in large numbers of animals. Clinical signs were recorded by observing the animals twice a day and by undisturbed 
videotaping. Videos were analyzed afterward. Body temperature was measured twice a day using both a 
temperature-sensitive transponder inserted subcutaneously and an external temperature monitor.  
The evaluation phase of the study focused on the types of clinical signs seen after challenge and the possibility of 
grouping clinical signs in successive stages. Additionally, body temperature was monitored before and after 
challenge. Table 1 shows the typical clinical signs of diseased animals and the order in which they occur. In 
addition to general clinical signs that occurred in all diseased animals, less common clinical signs were observed, 
such as circling, paralysis, and hypersensitivity. These clinical signs were not included in the stage categories. The 
first clinical signs related to virulent B. pertussis challenge were observed starting about three days after challenge.  
Typically, body temperature of diseased animals decreases. This finding was confirmed in all studies. A slight 
increase in body temperature was seen only in the early days after challenge; therefore, we concluded that decrease 
in body temperature reflects disease progress. Also, decreases in body temperature and body weight were translated 
to ranges in order to allow easy evaluation. The ranges and clinical stages are given in Table 2.  
In the validation phase of the study, predictivity and reliability of stages and ranges for death/survival in the 
observation period were assessed retrospectively for each individual animal in a series of routine batch release tests. 
A typical health monitoring sheet for two animals, one that died early in the observation period and one that died 
late in the observation period, is given in Tables 2a and 2b.  
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Table 1. Grouping of clinical signs after intracerebral challenge of mice with virulent B. pertussis 
Clinical Stages Cardinal Clinical Signsa 
0 Normal healthy animal 
1 Reduced alertness 
Dull fur (piloerection, poor grooming) 
Reduced food intake 
Less social contact 
2 Inactivity (lethargy) 
Hunched posture 
Social isolation 
No food and water intake 
Dehydration 
3 Same as stage 2 + 
General weakness (e.g., disturbed locomotor activity)  
Dehydration 
Emaciation 
4 Tonic and clonic convulsions (seizures) 




a Clinical signs within two days after challenge are attributed to the challenge procedure itself, and those animals were excluded from further 
study. 
 
Table 2a. Health monitoring sheet of clinical signsa, body weightb, and body temperaturec of an animal 
(Mouse 2.1) that died early after challenge (Day 14) 
 
Day 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
Clinical Stage     1 2 4 d        
Weight (%) 100 95 88 79 72 65 60         
Body temp. (0C)d 37.8 37.8 37.9 37.4 35.2 33.3 27.6         
a Clinical signs occurring at Days 14 and 15 were related to the challenge procedure. 
b Body weight loss ranges: 20 - 30%; 30 – 40%; 40 – 50%; > 50% 
c Body temperature drop ranges: 35.5 – 35.00C; 35.0 – 34.50C; 34.5 – 34.00C; <34.00C 
d Day animal died  
 
Table 2b. Health monitoring sheet of clinical signsa, body weight, and body temperature of an animal (Mouse 
1.3) that died late after challenge (Day 14) 
 
Day 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
Clinical Stage     1 1 2 2 3 3 3 3 3 b  
Weight (%) 100 92 88 76 70 65 64 66 57 58 55 53 51   
Body temp. (0C) 37.0 37.1 37.4 36.9 36.3 35.1 34.7 34.5 33.5 33.2 32.7 30.2 26.2   
a Clinical signs occurring at Days 14 and 15 were related to the challenge procedure. 
b Day animal died 
 
Two conditions were considered crucial for the validity of identified humane endpoint stages and ranges. The 
first condition was low frequency of both false positive predictions and false negative predictions. False positive 
means that, based on the endpoint stage/range, the animal would have been euthanized, while, in fact, the animal 
would have survived the observation period. False negative means that the animal had already died before the 
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endpoint stage/range had been reached. Table 3 shows the results of a typical study in which 76 animals were 
immunized with the reference wP preparation. In this experiment, 30 animals died during the observation period, 
while 46 animals survived. The number of false positive and false negative predictions is given, as well as the 
percentage of false positive and false negative predictions.  
An endpoint with a high frequency of false positive results would invalidate the potency study; an endpoint with 
a high frequency of false negative results would compromise an effective animal welfare policy. Consequently, the 
ideal endpoint would be the endpoint with a low frequency of false positive and a low frequency of false negative 
results. As can be seen from Table 3, a drop in body temperature to 34.5 - 34.00C and a clinical stage of 3 meet the 
conditions for predictivity. It also can be noted that a loss of body weight is not a valid endpoint in wP potency 
testing: a 20 - 30% body weight loss results in a high frequency of false positives, a body weight loss > 40% results 
in a high frequency of false negatives, while a body weight loss of 30 - 40% results in a high frequency of both false 
positives and false negatives.  
 
Table 3. False positive and false negative predictions when applying various endpoint criteria for humane 
euthanasia 
 
Humane Endpoint False positivea % False negativeb % 
Temperature     
35.5 – 35.00C 9 19.5 0 0 
35.0 – 34.50C 2 4.3 2 6.7 
34.5 – 34.00C 0 0.0 2 6.7 
< 34.00C 0 0.0 4 13.3 
Body weight loss     
20 – 30% 21 45.6 0 0.0 
30 – 40% 10 21.7 6 20.0 
40 – 50% 1 2.2 25 83.3 
> 50% 0 0.0 30 100.0 
Clinical stage     
1 22 47.8 0 0.0 
2 11 23.9 0 0.0 
3 1 2.7 2 6.7 
4 1 1.0 9 30.0 
a Animals surviving that exhibited the listed endpoint but would have been erroneously killed if the endpoint had been used. 
b Animals dying that did not exhibit the listed endpoint and thus would have died naturally and would not have been humanely killed if this 
endpoint had been used. 
4. Discussion 
In the presented study, we demonstrated that particular stages for body temperature and clinical signs are both 
relevant and reliable to replace death as the endpoint in a wP vaccine potency test. However, it should be kept in 
mind that endpoints cannot generally be transferred as such to other animal models. Thus, in our study, using the wP 
potency test as a case study, body weight appeared not to be a valid endpoint, while in other animal models, such as 
for rabies potency testing, body weight appeared to be predictive for death [10].  
With regard to body weight, for example, using intervals of 2 grams in the 30% to 50% body weight loss range 
could further refine endpoint stages. Also, combining scoring for two endpoints could refine predictivity.  
Regarding predictivity, most pharmacopoeias now accept the use of humane endpoints. However, an informal 
inquiry of vaccine manufacturers, performed by HELP several years after pharmacopoeias allowed the use of 
humane endpoints, showed that few manufacturers actually had implemented humane endpoint strategies 
(unpublished data). Although the reasons for reluctance may be diverse, several possibilities are suggested below: 
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• Clinical signs are generally subjective in nature, and interpretation differences might occur between observers.  
• Using humane endpoints implies that animals have to be observed more frequently than only once a day, which 
will increase labor costs of experiments. 
• Humane endpoints are model specific. Consequently, for each product, studies must be performed to identify 
humane endpoints and to validate predictivity. 
• Although use of humane endpoints has been implemented in most pharmacopoeias (without being a strict 
requirement), regulatory authorities in individual countries might still adhere to results obtained by lethal 
challenge. Manufacturers will react to the diversity in specifications by providing challenge results. 
Not all of the listed obstacles are easy to tackle. International acceptance of humane endpoints will require 
harmonization or mutual recognition of test requirements. Although this has been a key topic of discussion for quite 
some time, little progress has been made. Arguments can successfully be made in favor of implementing humane 
endpoints, including the facts that additional costs are limited and the subjectivity of monitoring clinical signs can be 
avoided with additional on-site training. Information on humane endpoints and clinical signs will be provided 
shortly on the website: www.humane-endpoints.info, which is a website of the Department of Animals in Science 
and Society of the Faculty of Veterinary Medicine, Utrecht University. 
Implementing humane endpoints in vaccine quality control does not result in scientific benefits or economic 
profits but is a matter of humane care and, consequently, of ethics. Although not responsible, regulatory authorities 
could play a role in encouraging implementation of humane endpoints when reviewing manufacturer’s submissions 
for lot release based on lethal challenge end-points.  
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